Clinical trial · Observational
Vaccine Responses in Cancer
NCT06605625CI-TRIAL-00096827VRiCactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Viral Vaccines | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Influenza vaccination | Biological | — | UNRESOLVED |
| SARS-CoV-2 vaccine | Biological | — | UNRESOLVED |
| Zoster Vaccine Recombinant | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with Cancer
- description
- Patients with cancer who are clinically indicated to receive influenza, recombinant shingles and/or SARS-CoV2 vaccine
- interventionNames
- Biological: Influenza vaccination
- Biological: SARS-CoV-2 vaccine
- Biological: Zoster Vaccine Recombinant
Primary outcomes (1)
- measure
- Neutralizing antibody response
- timeFrame
- 45-90 days
- description
- The neutralizing antibody titer will be assessed by measurement of the hemagglutinin-inhibition titer before and after influenza vaccination in order to determine the seroconversion rate. The late blood draw may occur between days 45-90 following vaccination.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * adults over age 18 who are able to provide consent, who have a diagnosis of cancer, and are willing to receive the influenza, recombinant shingles, and/or SARS-CoV-2 vaccines. Exclusion Criteria: * allergic to influenza, shingles, and/or SARS-CoV-2 vaccination; have HIV infection; have a history of solid organ or bone marrow transplant.
References
Publications (0)
Data not yet available
No reference posted for this study.